Determination of ESR1 mutations
PreclinicalBiologic
Determination of ESR1 mutations is one of 79 biologic programs targeting Breast Cancer. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Blenoxane
Bristol-Myers SquibbPreclinical
Spravato
WWim Janssens
Preclinical
Duragesic
CCephalon
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Beta Blocker
WWeill Medical College of Cornell University
Preclinical
Metfomin
UUniversity of Texas Southwestern Medical Center
Preclinical
Bisphosphonate
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- CCentre Henri Becquerel